Fully-funded PhD studentship: Unmasking mechanisms of resistance to KRAS inhibition across pancreatic cancer genetic profiles

Supervisor: Dr Giulia Biffi Department/location: Cancer Research UK Cambridge Institute Deadline for application: 16th October 2026 Course start date: 1st October 2027 Project details For further information about the research group, including their most recent publications, please visit their website at Pancreatic ductal adenocarcinoma (PDAC) remains a formidable clinical challenge. A major recent advance has been the development of KRAS inhibitors, which have shown considerable promise in clinical trials (1). For decades, KRAS was considered undruggable; however, these new inhibitors represent a potential turning point for patients with PDAC. Despite this progress, rapid therapy resistance has already been observed in both patients and pre-clinical mouse models, highlighting the urgent need to define the mechanisms that drive resistance and to identify rational combination therapies.